AMONDYS 45 Drug Patent Profile
✉ Email this page to a colleague
When do Amondys 45 patents expire, and what generic alternatives are available?
Amondys 45 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are six patents protecting this drug.
This drug has eighty-seven patent family members in twenty-four countries.
The generic ingredient in AMONDYS 45 is casimersen. One supplier is listed for this compound. Additional details are available on the casimersen profile page.
DrugPatentWatch® Generic Entry Outlook for Amondys 45
Amondys 45 will be eligible for patent challenges on February 25, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 12, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMONDYS 45?
- What are the global sales for AMONDYS 45?
- What is Average Wholesale Price for AMONDYS 45?
Summary for AMONDYS 45
| International Patents: | 87 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in AMONDYS 45? | AMONDYS 45 excipients list |
| DailyMed Link: | AMONDYS 45 at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for AMONDYS 45
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for AMONDYS 45
| Drug Class | Antisense Oligonucleotide |
| Physiological Effect | Increased Protein Synthesis |
US Patents and Regulatory Information for AMONDYS 45
AMONDYS 45 is protected by eight US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of AMONDYS 45 is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting AMONDYS 45
Antisense molecules and methods for treating pathologies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Antisense molecules and methods for treating pathologies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION
Antisense molecules and methods for treating pathologies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Antisense molecules and methods for treating pathologies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
Antisense molecules and methods for treating pathologies
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
FDA Regulatory Exclusivity protecting AMONDYS 45
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AMONDYS 45
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | ⤷ Sign Up | ⤷ Sign Up |
| Sarepta Theraps Inc | AMONDYS 45 | casimersen | SOLUTION;INTRAVENOUS | 213026-001 | Feb 25, 2021 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AMONDYS 45
When does loss-of-exclusivity occur for AMONDYS 45?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 10317599
Patent: Antisense molecules and methods for treating pathologies
Estimated Expiration: ⤷ Sign Up
Patent: 16202924
Patent: Antisense molecules and methods for treating pathologies
Estimated Expiration: ⤷ Sign Up
Patent: 18202105
Patent: Antisense Molecules and Methods for Treating Pathologies
Estimated Expiration: ⤷ Sign Up
Patent: 20260498
Patent: Antisense Molecules and Methods for Treating Pathologies
Estimated Expiration: ⤷ Sign Up
Patent: 23203103
Patent: Antisense Molecules and Methods for Treating Pathologies
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012011195
Patent: OLIGONUCLEOTÍDEO ANTISSENTIDO, COMPOSIÇÃO E RESPECTIVO USO.
Estimated Expiration: ⤷ Sign Up
Patent: 2023023194
Patent: Oligonucleotídeo antissentido, composição e respectivo uso
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 80563
Patent: MOLECULES ANTISENS ET PROCEDES DE TRAITEMENT DE PATHOLOGIES (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
China
Patent: 3003430
Patent: Antisense molecules and methods for treating pathologies
Estimated Expiration: ⤷ Sign Up
Patent: 5838714
Patent: 反义分子和治疗疾病的方法 (Antisense molecules and methods for treating pathologies)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0181824
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 21198
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 99249
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 99249
Patent: MOLÉCULES ANTISENS ET PROCÉDÉS DE TRAITEMENT DE PATHOLOGIES (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Patent: 31603
Patent: MOLÉCULES ANTISENS ET PROCÉDÉS DE TRAITEMENT DE PATHOLOGIES (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 40445
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9753
Patent: אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
Estimated Expiration: ⤷ Sign Up
Patent: 5707
Patent: אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
Estimated Expiration: ⤷ Sign Up
Patent: 4525
Patent: אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
Estimated Expiration: ⤷ Sign Up
Patent: 6947
Patent: אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
Estimated Expiration: ⤷ Sign Up
Patent: 7299
Patent: אוליגונוקלאוטידי אנטיסנס לגרימת דילוג אקסון בגן דיסטרופין (Antisense oligonucleotides for inducing exon skipping in the dystrophin gene)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 63678
Estimated Expiration: ⤷ Sign Up
Patent: 94393
Estimated Expiration: ⤷ Sign Up
Patent: 25449
Estimated Expiration: ⤷ Sign Up
Patent: 36830
Estimated Expiration: ⤷ Sign Up
Patent: 13510561
Estimated Expiration: ⤷ Sign Up
Patent: 16198105
Patent: 病状を治療するためのアンチセンス分子及び方法 (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Patent: 18082714
Patent: 病状を治療するためのアンチセンス分子及び方法 (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Patent: 19141073
Patent: 病状を治療するためのアンチセンス分子及び方法 (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Patent: 22001053
Patent: 病状を治療するためのアンチセンス分子及び方法 (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Patent: 24029262
Patent: 病状を治療するためのアンチセンス分子及び方法 (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 99249
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 6359
Patent: Antisense molecules and methods for treating pathologies
Estimated Expiration: ⤷ Sign Up
Patent: 6534
Patent: Antisense molecules and methods for treating pathologies
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 99249
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 99249
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 079
Patent: ANTISENS MOLEKULI I POSTUPCI ZA TRETMAN PATOLOGIJA (ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES)
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 99249
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1958491
Estimated Expiration: ⤷ Sign Up
Patent: 2000762
Estimated Expiration: ⤷ Sign Up
Patent: 2113306
Estimated Expiration: ⤷ Sign Up
Patent: 2239374
Estimated Expiration: ⤷ Sign Up
Patent: 2366851
Estimated Expiration: ⤷ Sign Up
Patent: 2487132
Estimated Expiration: ⤷ Sign Up
Patent: 2581868
Estimated Expiration: ⤷ Sign Up
Patent: 130084595
Patent: ANTISENSE MOLECULES AND METHODS FOR TREATING PATHOLOGIES
Estimated Expiration: ⤷ Sign Up
Patent: 180004745
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Patent: 190084360
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Patent: 200055161
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Patent: 210041130
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Patent: 220031125
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Patent: 230010814
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Patent: 230137491
Patent: 안티센스 분자 및 이를 이용한 질환 치료방법 (Antisense Molecules and Methods for Treating Pathologies)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 93459
Estimated Expiration: ⤷ Sign Up
Turkey
Patent: 1816523
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering AMONDYS 45 around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
